Gilead Sciences Shoots for 1st All-Oral Hepatitis C Regimen
Four months after passing on an opportunity to pursue Phase III trials of its hepatitis C drug GS-7977 in combination with Bristol-Myers Squibb Co.'s daclatasvir, Gilead Sciences Inc. has confirmed that it will go it alone instead, pressing ahead with its in-house NS5A inhibitor GS-5885.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter